ARTL
ARTELO BIOSCIENCES, INC.
Next earnings Aug 11, 2026
$1.12
▼ -3.45%$1.12▼ -93.53%
over 1Y
L $1.12EODHDH $85.50
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.4%
1W-8.9%
1M-17.6%
3M-89.4%
YTD-70.6%
1Y-93.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity -3.20x).
ARTELO BIOSCIENCES, INC. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.44M | -$10.3M | -$9.93M | -$10.1M | -$11.4M |
| Net income | -$7.44M | -$10.1M | -$9.29M | -$9.83M | -$12.9M |
| Diluted EPS | — | — | -$3.14 | -$18.30 | -$12.52 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.78M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-541.2%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$600K
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-35.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-05-15). Worth a closer look.
- DEF 14A Proxy statement2026-06-05
- 8-K Material agreement2026-05-27
- 8-K Agreement terminated2026-05-15
- 10-Q Quarterly report2026-05-14
- S-3/A Shelf registration (potential raise)2026-05-14
- S-3 Shelf registration (potential raise)2026-05-04
- 8-K Other event2026-04-07
- S-1 Securities registration2026-04-07
- 8-K Material agreement2026-03-30
Recent filings
all on EDGAR ↗PRER14AFiling2026-06-22open ↗ARSPeriod ending 2025-12-312026-06-05open ↗DEFA14AFiling2026-06-05open ↗DEF 14APeriod ending 2026-07-172026-06-05open ↗8-KPeriod ending 2026-05-262026-05-27open ↗PRE 14APeriod ending 2026-07-172026-05-26open ↗424B5Filing2026-05-26open ↗EFFECTFiling2026-05-19open ↗424B5Filing2026-05-18open ↗8-KPeriod ending 2026-05-112026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗
Frequently asked
- Is ARTELO BIOSCIENCES, INC. (ARTL) a buy?
- ARTL currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -3.20x).
- What is ARTELO BIOSCIENCES, INC.'s quality score?
- ARTL scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001621221, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:48:43 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.